Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Gross Margin (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Gross Margin for 16 consecutive years, with 62.65% as the latest value for Q4 2025.

  • On a quarterly basis, Gross Margin rose 668.0% to 62.65% in Q4 2025 year-over-year; TTM through Dec 2025 was 56.56%, a 628.0% increase, with the full-year FY2025 number at 56.56%, down 682.0% from a year prior.
  • Gross Margin was 62.65% for Q4 2025 at Anika Therapeutics, up from 56.02% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 89.07% in Q2 2024 to a low of 199.14% in Q4 2023.
  • A 5-year average of 34.71% and a median of 57.4% in 2021 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: plummeted -18607bps in 2022, then surged 25510bps in 2024.
  • Anika Therapeutics' Gross Margin stood at 50.62% in 2021, then crashed by -368bps to 135.45% in 2022, then tumbled by -47bps to 199.14% in 2023, then surged by 128bps to 55.96% in 2024, then grew by 12bps to 62.65% in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Gross Margin are 62.65% (Q4 2025), 56.02% (Q3 2025), and 50.9% (Q2 2025).